With the follow-up time ranging from 1 to 132 months, the median DFS of the four groups (NBNC-AFP(+)/(-)-HCC groups and B-AFP(+)/(-)-HCC groups) was 15 months, 90 months, 10 months, and 24 months, respectively, and their corresponding 1-year DFS was 50.3%, 84.6%, 47.3%, and 50.1%, while their 2-year DFS was 43.1%, 72.9%, 42.3%, and 42.9%. This evidence concerns the gene AFP and hepatocellular carcinoma.